Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Recursion Pharmaceuticals Inc (RXRX) vs Uranium Energy Corp (UEC) Price & Performance

Recursion Pharmaceuticals IncTrade
Uranium Energy CorpTrade

Price performance (Past 24H)

Key statistics

Recursion Pharmaceuticals Inc vs Uranium Energy Corp — how do they compare? Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B), while Uranium Energy Corp trades at $11.43 (market cap $5.67B). The key difference: Uranium Energy Corp is far larger — about 3.1× Recursion Pharmaceuticals Inc's market cap, and Uranium Energy Corp is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

RXRXUEC
Market Cap
$1.81B$5.67B
Sector
HealthEnergy
52-Week High
$6.79$20.14
52-Week Low
$2.84$9.04
Enterprise Value
$1.33B$5.18B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Recursion Pharmaceuticals Inc

RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.

Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.

Uranium Energy Corp

UEC trades at $11.64, up 2.28% today, with a bullish technical signal from moving averages. The company reported a net loss of $87.66 million in 2025 despite $66.84 million revenue, with negative profit margins and cash flow challenges. Recent news highlights insider selling and ongoing uranium market optimism. Analyst consensus is strongly bullish with 87.5% buy ratings, though fundamentals show significant financial strain.

UEC presents high-risk exposure to uranium market growth with substantial operational losses and negative cash flow from operations. The stock's premium valuation (P/S 267.84) relies heavily on future nuclear energy adoption, while current financials indicate dependency on financing activities. Near-term catalysts include production ramp-up and licensing approvals, but execution risks and cost pressures remain elevated.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX

About Uranium Energy Corp

Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.

Read more on UEC